Search Results

You are looking at 181 - 190 of 868 items for :

  • Refine by Access: All x
Clear All
Full access

Who Benefits From Maintenance Therapy in Acute Promyelocytic Leukemia?

Edmond Marzbani and Elihu Estey

-containing chemotherapy and achieves molecular remission rates of 95%. Standard practice is including ATRA in consolidation, because historical comparisons suggest reduced relapse risk when used in conjunction with chemotherapy. Evidence has emerged that in high

Full access

CLO20-041: Prognostic Factors in Major Salivary Gland Tumors Treated with Adjuvant Radiation Therapy

Jung Julie Kang, Hannah Verma, Kaveh Zakeri, Huili Wang, Dan Fan, Ming Fan, Anna Lee, Sarin Kitpanit, Linda Chen, Yao Yu, C. Jillian Tsai, Sean McBride, Nadeem Riaz, Daphna Gelblum, Alan S. Ho, Eric Sherman, Lara Dunn, Jay O. Boyle, Richard J. Wong, Ian Ganly, and Nancy Y. Lee

RT at Memorial Sloan Kettering Cancer Center from 2010 to 2018 were retrospectively reviewed. The Kaplan-Meier method was used to estimate local relapse free survival (LRFS), regional relapse free survival (RRFS), distant metastasis free survival

Full access

Oncology Research Program

scientific peer-review process and are overseen by the ORP. An NCCN study funded through the grant mechanism is highlighted below. Carfilzomib Plus Belinostat in Relapsed/Refractory Non-Hodgkin's Lymphoma Subtypes: A Phase I Study Principal

Full access

Updates to the Management of Chronic Lymphocytic Leukemia

William G. Wierda

, including elderly patients and those with relapsed or refractory del(17p), in terms of overall response rate, duration of response, and PFS. In the phase III trial, 9 where ibrutinib was compared with ofatumumab in relapsed or refractory disease, overall

Full access

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology

William G. Wierda, John C. Byrd, Jeremy S. Abramson, Syed F. Bilgrami, Greg Bociek, Danielle Brander, Jennifer Brown, Asher A. Chanan-Khan, Julio C. Chavez, Steve E. Coutre, Randall S. Davis, Christopher D. Fletcher, Brian Hill, Brad S. Kahl, Manali Kamdar, Lawrence D. Kaplan, Nadia Khan, Thomas J. Kipps, Megan S. Lim, Shuo Ma, Sami Malek, Anthony Mato, Claudio Mosse, Mazyar Shadman, Tanya Siddiqi, Deborah Stephens, Suchitra Sundaram, Nina Wagner, Mary Dwyer, and Hema Sundar

-stimulated karyotype of CLL cells) may be a stronger predictor of poor clinical outcomes than del(17p) or TP53 mutation in patients with CLL treated with ibrutinib-based regimens. 59 – 64 In a multivariate analysis, among patients with relapsed/refractory CLL

Full access

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016

Kenneth C. Anderson, Melissa Alsina, Djordje Atanackovic, J. Sybil Biermann, Jason C. Chandler, Caitlin Costello, Benjamin Djulbegovic, Henry C. Fung, Cristina Gasparetto, Kelly Godby, Craig Hofmeister, Leona Holmberg, Sarah Holstein, Carol Ann Huff, Adetola Kassim, Amrita Y. Krishnan, Shaji K. Kumar, Michaela Liedtke, Matthew Lunning, Noopur Raje, Frederic J. Reu, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Donna Weber, Joachim Yahalom, Dorothy A. Shead, and Rashmi Kumar

(ISS) developed by the International Myeloma Working Group (IMWG), (2) new regimen options for the treatment of newly diagnosed MM, and (3) recent FDA-approved novel drug–containing regimens for the treatment of relapsed/refractory MM. Diagnostic

Full access

Patient Case Studies and Panel Discussion: Lymphoma

significantly better; however, relapse is associated with poor patient outcomes. “The ongoing challenge is to achieve higher CR rates and to translate those remissions into long-term survival,” said Dr. Advani. Another treatment option is the CHOEP regimen

Full access

Updates in the Management of CLL/SLL: Sequencing Therapy and the Role of Minimal Residual Disease Testing

Presented by: William G. Wierda

several years, and then retreat them when the disease relapses,” Dr. Wierda explained. In patients with mutated IGHV , FCR should still be considered. “I'm optimistic that eventually that will be replaced by venetoclax-based therapy,” he said. “But we

Full access


Anderson Cancer Center, summarized data from clinical trials that led to the approval of ibrutinib and idelalisib (small molecule inhibitors of B-cell receptor signalling pathways) for the management of heavily pretreated relapsed/refractory CLL with del

Full access

Complications of Multiple Myeloma Therapy, Part 1: Risk Reduction and Management of Peripheral Neuropathy and Asthenia

Paul G. Richardson, Jacob P. Laubach, Robert L. Schlossman, Constantine Mitsiades, and Kenneth Anderson

RVD treatment in 64 patients with relapsed and/or refractory MM, only 1 case of grade 3 PN was seen, which occurred despite bortezomib reduction and required treatment discontinuation but subsequent improvement followed. 54 This suggests that such